Back

De-escalation of antiplatelet therapy after percutaneous coronary intervention in acute coronary syndrome patients: outcome of diabetics in the randomized TROPICAL-ACS trial

26 August 2018 (15:50 - 16:40)
Organised by:
Congress Presentation Part of: Diabetes-associated coronary artery disease Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Ralph Hein

Clinic Dritter Orden, Munich (Germany)

6 More presentations in this session

Presentation thumbnail
Long-term safety and efficacy of the xience everolimus eluting stent in patients at high bleeding risk: a patient-level pooled analysis from four xience post-approval trials
Doctor R. Mehran (New York City, US)
Abstract Slides
Presentation thumbnail
Diagnostic performance of quantitative flow ratio in diabetic and non-diabetic patients
Mr J. Smit (Leiden, NL)
Abstract Slides
Presentation thumbnail
A clinical risk score to predict the presence of obstructive coronary artery disease in asymptomatic patients with type 2 diabetes
Assistant Professor C. Kim (Uijungbu, KR)
Abstract Slides
Presentation thumbnail
Impact of glycated hemoglobin in diabetic patients with coronary artery disease undergoing surgery, angioplasty or clinical treatment in a very long-term follow-up
Mr E. Martins (Sao Paulo, BR)
Abstract Slides
Presentation thumbnail
Prognostic impact of admission hyperglycemia in acute coronary syndrome patients and its interaction with diabetes mellitus history and metabolic control.
Doctor J. Alves Guimaraes (Vila Real, PT)
Abstract Slides

Access the full session

Session thumbnail
Diabetes-associated coronary artery disease

The Event

Event poster

ESC Congress 2018

26 August 2018 15:50 CET
You may be interested in
thumbnail
Congress Presentation
Atherothrombotic risk and outcomes following guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome:a post-hoc analysis of the TROPICAL-ACS trial
2 September 2019
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI
26 May 2025
thumbnail
Webinar
The EAPCI Journal Club: T-PASS Randomised Trial
14 November 2023
thumbnail
Congress Presentation
Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources